Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respironics grows sleep disorder business with Apollo buy:

This article was originally published in Clinica

Executive Summary

Sleep and respiratory treatment specialist Respironics has expanded its reach in the sleep disorder therapy market with the purchase of Apollo Light Systems for $6.5m. Murrysville, Pennsylvania-based Respironics, which is looking to broaden its scope beyond its core business of treating obstructive sleep apnea, will add Apollo's light therapy systems for melatonin suppression and circadian rhythm sleep disorders to its Sleep Well Ventures business. The deal will see additional payments made by Respironics to Apollo based on the latter's operating performance over the next year. Apollo (American Fork, Utah) generates annual revenues of around $5m from sales of its briteLITE and goLITE light therapy systems and its Daybreak Sunrise simulators.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel